Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
DALLAS, December 10, 2013 /PRNewswire/ --
The "Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in the U.S., Canada, U.K., France, Germany, Italy, Spain, and Japan.
Browse 50 Market Data Tables and 28 Figures spread through 157 Pages and in-depth TOC on "Acute Lymphocytic Leukemia Therapeutics Market"
Early buyers will receive 10% customization on this report.
This report studies the Acute Lymphocytic Leukemia Therapeutics Market, with forecast to 2020.
The Acute Lymphocytic Leukemia Therapeutics Market has experienced stagnant growth in the past few years. The increasing incidence rate of Acute Lymphocytic Leukemia and upcoming innovative therapies are the major factors that further propel the growth of this market. However, the high costs of therapies as well as the adverse events associated with therapies are factors that inhibit the growth of the market to a certain extent.
According to the WHO, Acute Lymphocytic Leukemia Therapeutics Market is expected to be more widespread in the developed countries and higher socioeconomic groups, such as North America and the European countries due to genetic factors. Other causes like environmental factors and exposure to high doses of radiation are also the causative factors of all the types of Acute Lymphocytic Leukemia.
The U.S. has the largest market in 2013 with a market share of approximately 55% to 60% of the Acute Lymphocytic Leukemia Therapeutics Market in G8 countries, followed by Germany and Italy.
Major players in the market include ERYTECH Pharma (France), Talon Therapeutic, Inc. (U.S.), Pfizer, Inc. (U.S.) GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), and Genzyme Corporation (U.S.).
Browse Related Reports
Biosimilars Market - Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018
Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 - 2018)
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, agriculture industry, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
©2012 PR Newswire. All Rights Reserved.